 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- | libvatrep oral (SAF312) / Novartis
Journal: Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep). (Pubmed Central) - Sep 8, 2023
SAF312 is a potent, selective, and noncompetitive antagonist of hTRPV1 with an acceptable preclinical safety profile for use in future clinical trials. SAF312, which was safe and well tolerated without causing delay in wound healing after PRK in rabbits, may be a potential therapeutic agent for ocular surface pain.
- | Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, libvatrep oral (SAF312) / Novartis, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Ocular surface itch and pain: key differences and similarities between the two sensations. (Pubmed Central) - Aug 31, 2023
Identifying contributors to abnormal ocular sensations is vital for precise medical care. Novel therapeutics for these conditions aim to improve patient outcomes and quality of life.
- | libvatrep oral (SAF312) / Novartis
Journal: Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) for Postoperative Pain After Photorefractive Keratectomy. (Pubmed Central) - Mar 15, 2023
SAF312 was well tolerated and effective in reducing ocular pain post-PRK. Topical SAF312 presents a new therapeutic option for patients undergoing PRK.
- | libvatrep oral (SAF312) / Novartis
Journal: Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants. (Pubmed Central) - Nov 18, 2022
SAF312 was well tolerated, with no ocular or systemic safety concerns; had no anesthetic effect, and demonstrated rapid topical absorption with low systemic exposure. This work bridges the gap between basic research and clinical care by providing FIH data of SAF312, supporting the further investigation as a potential treatment for ocular surface pain.
- libvatrep oral (SAF312) / Bausch Health
Trial termination: Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions (clinicaltrials.gov) - Feb 20, 2013
P2, N=9, Terminated, Sponsor: Novartis Pharmaceuticals
This work bridges the gap between basic research and clinical care by providing FIH data of SAF312, supporting the further investigation as a potential treatment for ocular surface pain. Recruiting --> Terminated
- libvatrep oral (SAF312) / Bausch Health
Enrollment change: Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions (clinicaltrials.gov) - Feb 20, 2013
P2, N=9, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated N=36 --> 9
- libvatrep oral (SAF312) / Bausch Health
Trial initiation date: Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions (clinicaltrials.gov) - Sep 20, 2012
P2, N=9, Terminated, Sponsor: Novartis Pharmaceuticals
N=36 --> 9 Initiation date: Jul 2011 --> Jan 2012
- libvatrep oral (SAF312) / Bausch Health
New P2 trial: Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions (clinicaltrials.gov) - May 13, 2012
P2, N=9, Terminated, Sponsor: Novartis Pharmaceuticals
- |||| libvatrep oral (SAF312) / Bausch Health
Trial completion: To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients (clinicaltrials.gov) - Oct 4, 2011
P2, N=214, Completed, Sponsor: Novartis
Initiation date: Jul 2011 --> Jan 2012 Recruiting --> Completed